LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback